Építés alatt – nem éles oldal
Belépés
Leállítva1. fázis

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

A legfontosabb adatok

Ki végzi
Prelude Therapeutics Incorporated
Hol
Bethesda, Brick, Canton, Houston, New York, Orange City, Orlando, Philadelphia és Port Jefferson Station (Egyesült Államok)Mind a 9 helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
1. fázis
Résztvevők
21 fő vett részt
Kezdés
2022. márc. 22.
Befejezés
2024. jan. 19.
A vizsgálat típusa
Beavatkozással járó, 3 csoport
A vizsgált kezelések
  • PRT1419
  • Azacitidine
  • Venetoclax
A regiszteradat frissítve
2024. január 31.
Miért állt le
Company Decision

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures
  • Refractory/relapsed disease, having progressed on prior treatment, and without access to further approved therapies or ineligible for approved therapies, in one of the following disease categories: AML, CMML, MDS, MDS/MPN Overlap Syndrome, CLL/SLL, and B-cell NHLs
  • Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 to 2
  • Adequate organ function (hematology, hepatic, renal, and coagulation)

Ki nem vehet részt

  • Treatment with either OATP1B1, OATP1B3 substrates or strong inhibitors of CYP2C8, CYP3A4, and any medication contraindicated in combination with AZA or VEN
  • Prior exposure to an MCL-1 inhibitor
  • Active inflammatory disorders of the gastrointestinal tract, a history of bariatric surgery or other disorders with the potential for GI malabsorption
  • Cardiac function compromise, as assessed by echocardiogram or protocol-specified biochemical markers of cardiac damage, or protocol-defined clinically significant heart disease
  • History of cerebrovascular accident or transient ischemic attack, within 6 months of screening. Participants with a history of pulmonary embolism must not be symptomatic at enrollment
  • Undergone hematopoietic stem-cell transplantation (HSCT) within the last 90 days or have graft-versus-host disease (GVHD) Grade > 1 at study entry
  • Uncontrolled intercurrent illnesses, poorly controlled hypertension or dyslipidemias, Unstable central nervous system (CNS) metastases
  • Within 5 half-lives or 14 days (whichever is longer) following the last systemic anti-cancer therapy
  • History of another malignancy except for:; Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical or breast carcinoma in situ without evidence of disease; Asymptomatic prostate cancer without known metastatic disease and no requirement for therapy or requiring only hormonal therapy and with normal prostate specific antigen for >1 year prior to enrollment; Other malignancy treated with curative intent with no known active disease for > 2 years prior to enrollment

Helyszínek itt: Egyesült Államok

  • American Oncology Partners of Maryland, PABethesda, Egyesült Államok
  • New Jersey Center for Cancer ResearchBrick, Egyesült Államok
  • Gabrail Cancer Center ResearchCanton, Egyesült Államok
  • The University of Texas MD Anderson Cancer CenterHouston, Egyesült Államok
  • Memorial Sloan Kettering Cancer Center - Main CampusNew York, Egyesült Államok
  • Mid Florida Hematology and oncology CenterOrange City, Egyesült Államok
  • AdventHealth Bone and Marrow Transplant CenterOrlando, Egyesült Államok
  • Thomas Jefferson University, Sidney Kimmel Cancer CenterPhiladelphia, Egyesült Államok
  • North Shore Hematology Oncology Associates Dba New York Cancer and Blood SpecialistsPort Jefferson Station, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia-1 (MCL-1) inhibitor, in participants with selected relapsed/refractory myeloid or B-cell malignancies. The purpose of this study is to evaluate the safety and tolerability of PRT1419 monotherapy and in combination with either azacitidine or venetoclax, describe any dose limiting toxicities (DLTs), define the dosing schedule, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

A vizsgálat 3 csoportja

  • PRT1419 MonotherapyA vizsgált kezelés

    PRT1419 will be administered by intravenous infusion once weekly on a 28-day treatment cycle at the dose level assigned.

    Kezelés: PRT1419

  • PRT1419/Azacitidine CombinationA vizsgált kezelés

    PRT1419 will be administered by intravenous infusion once weekly on a 28-day treatment cycle at the dose level assigned and Azacitidine will be administered by intravenous or subcutaneous on Days 1 through 7 (or alternatively on Days 1 through 5, 8 and 9) of each 28-day treatment cycle.

    Kezelés: PRT1419 és Azacitidine

  • PRT1419/Venetoclax CombinationA vizsgált kezelés

    PRT1419 will be administered by intravenous infusion once weekly on a 28-day treatment cycle at the dose level assigned and Venetoclax will be administered orally after either a 3-day or 5-week ramp-up period to reach 400 mg daily administration, prior to commencing PRT1419 administration.

    Kezelés: PRT1419 és Venetoclax

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection as Monotherapy or in Combination With Azacitidine or Venetoclax in Patients With Relapsed/Refractory Myeloid or B-cell Malignancies
A regiszteradat frissítve
2024. január 31.